Macular Neovascularization type influence on anti-VEGF intravitreal therapy outcomes in Age-related Macular Degeneration.
Age-related Macular degeneration
aflibercept
audit
benchmark standard
bevacizumab
neovascular AMD
outcome
ranibizumab
subtype
Journal
Ophthalmology. Retina
ISSN: 2468-6530
Titre abrégé: Ophthalmol Retina
Pays: United States
ID NLM: 101695048
Informations de publication
Date de publication:
02 Nov 2023
02 Nov 2023
Historique:
received:
25
10
2023
revised:
27
10
2023
accepted:
27
10
2023
medline:
5
11
2023
pubmed:
5
11
2023
entrez:
4
11
2023
Statut:
aheadofprint
Résumé
To evaluate the influence of macular neovascularization (MNV) lesion type on 12 months clinical outcomes in treatment-naïve eyes with age-related macular degeneration (nAMD) eyes treated with anti-vascular endothelial growth factor (VEGF) drugs nationwide. Multicenter national nAMD database observational study. One thousand six-hundred six treatment-naïve nAMD eyes (1330 patients) undergoing Anti-VEGF therapy for 12 months nationwide. Demographics, visual acuity (VA) in logarithm of the minimum angle of resolution (logMAR) letters, number of injections and visits data was collected using a validated web-based tool. Neovascular lesion phenotype was classified as type 1 (T1, n=711), type 2 (T2, n=505), type 3 (T3, n=315) and aneurysmal type 1 (A-T1, n=75), according to the new proposed consensus classification. Mean VA change at 12 months, final VA at 12 months, number of injections, time to lesion inactivation. A total of 1606 treatment-naïve nAMD eyes (1330 patients) received a median of 7 injections over 12 months. Mean (±standard deviation) baseline VA was significantly lower for T2 (49.4±23.5 letters) compared to T1 (57.8±20.8) and T3 (58.2 ±19.4)(both p<0.05) lesions. Mean VA change at 12 months was significantly greater for A-T1 (+9.5 letters) compared to T3 (+3.1 letters, p<0.05). T3 lesions had fewer active visits (24.9%) than the other lesion types (T1 30.5%, T2 32.6%, A-T1 27.5%, all p<0.05). Aflibercept was the most used drug in A-T1 lesions (70.1%) and ranibizumab in T1 (40.7%), T2 (57.7%) and T3 (47.6%) lesions. This study highlights the relevance of MNV type on clinical outcomes in nAMD and reports significant differences in baseline VA, VA change and lesion activity at 12 months. This report provides data about lesion-specific clinical features, which may guide the management of nAMD cases and potentially support a personalized clinical decision making in these patients.
Identifiants
pubmed: 37924946
pii: S2468-6530(23)00573-0
doi: 10.1016/j.oret.2023.10.022
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Investigateurs
Javier Zarranz-Ventura
(J)
Alba Parrado-Carrillo
(A)
Marc Figueras-Roca
(M)
Aina Moll-Udina
(A)
Jordi Izquierdo-Serra
(J)
Alba Serrano
(A)
Jose Grau
(J)
Carolina Bernal-Morales
(C)
Socorro Alforja
(S)
Ricardo P Casaroli-Marano
(RP)
Laura Sararols-Ramsay
(L)
Gabriel Londoño
(G)
Maximiliano Olivera
(M)
Karim Bañon
(K)
Cynthia Rethati
(C)
Pilar Calvo
(P)
Jorge Sánchez
(J)
Martín Puzo
(M)
Oscar Ruiz-Moreno
(O)
Gonzaga Garay-Aramburu
(G)
Arantza Larrauri-Arana
(A)
Angela Gómez-Moreno
(A)
David Rodríguez-Feijoo
(D)
Enrique Diaz-de-Durana-Santa-Coloma
(E)
Maialen Aldazabal-Echeveste
(M)
Zuriñe Del-Barrio-Lopez-de-Ipiña
(Z)
Irene Herrero-Díaz
(I)
José García-Arumí
(J)
Helena Brosa
(H)
Laura Sánchez-Vela
(L)
Miguel Angel Zapata
(MA)
Carolina Arruabarrena
(C)
Rafael Montejano-Milner
(R)
Fernando de Aragón
(F)
Maximino José Abraldes López-Veiga
(MJ)
María Lidia Gómez Conde
(ML)
María José Rodríguez-Cid
(MJ)
María Isabel Fernández Rodríguez
(MI)
Pablo Almuiña Varela
(PA)
Ana Fernández-Hortelano
(A)
Jesús Zarallo-Gallardo
(J)
Rosario Cobo-Soriano
(R)
Inmaculada Lozano-Escobar
(I)
Paula Moreno-Martín
(P)
Jose Ma Ruiz Moreno
(JM)
Rocío Vega-González
(R)
María García Zamora
(MG)
Ignacio Flores-Moreno
(I)
Xavier Valldeperas
(X)
Laura Broc-Iturralde
(L)
Ferran Vilaplana Mira
(FV)
Sandra Gómez Sánchez
(SG)
Pamela Campos Figueroa
(PC)
Jose Juan Escobar-Barranco
(JJ)
Manel Fernandez-Bonet
(M)
Begoña Pina-Marín
(B)
Eva Salinas Martínez
(ES)
Jacobo González Guijarro
(JG)
Muxima Acebes García
(MA)
Sonia Aparicio Sanchís
(SA)
Jonathan Cacelliere Fernández
(JC)
Marta Belmonte Grau
(MB)
Francisco Javier Ascaso Puyuelo
(FJ)
Ana Honrubia Grijalbo
(AH)
Ana Boned Murillo
(AB)
María Dolores Díaz Barreda
(MD)
Guillermo Pérez Rivasés
(GP)
Ismael Bakkali El Bakkali
(IB)
Roberto Gallego-Pinazo
(R)
Marta Cholbi
(M)
Rosa Dolz-Marco
(R)
Marta S Figueroa
(MS)
Esther Ciancas
(E)
Julio José Gonzalez-López
(JJ)
Cesar Azrak Haskour
(CA)
Alvaro Piñero Sánchez
(AP)
Nélida Muñoz Sanz
(NM)
Ester Carreño
(E)
Nestor Ventura
(N)
Pablo Carnota-Méndez
(P)
Carlos Méndez-Vázquez
(C)
Carlos Torres-Borrego
(C)
Daniel Velázquez-Villoria
(D)
Alfredo García-Layana
(A)
Manuel Saenz de Viteri
(M)
Elena Alonso
(E)
Luis J Castillón Torre
(LJ)
Pablo Catalán Muñoz
(PC)
María Eugenia Tena Sempere
(ME)
María de Fátima Álvarez Gil
(M)
Purificación Piñas García
(PP)
María Eugenia Mantrana Bermejo
(ME)
Francisco Javier Lavid de Los Mozos
(FJ)
Mónica Asencio Duran
(MA)
Lluis Arias-Barquet
(L)
Estefanía Cobos Martín
(EC)
Daniel Lorenzo Parra
(DL)
Marta Rodríguez-Núñez
(M)
Ana Campo Gesto
(AC)
Jesús Pareja Esteban
(JP)
María Del Pilar Ruiz Del Tiempo
(MDPRD)
Mariano Rodríguez-Maqueda
(M)
María Angeles Espiñeira Periñan
(MA)
Magdalena Sotomayor Toribio
(MS)
Informations de copyright
Copyright © 2023. Published by Elsevier Inc.